References
- Folgori L, Bielicki J, Heath PT, Sharland M. Antimicrobial-resistant gram-negative infections in neonates: burden of disease and challenges in treatment. Curr Opin Infect Dis. 2017;30:281–288.
- Zarrilli R, Bagattini M, Esposito EP, Triassi M. Acinetobacter infections in neonates. Curr Infect Dis Rep. 2018;20:48.
- Logan LK. Carbapenem-resistant enterobacteriaceae: an emerging problem in children. Clin Infect Dis. 2012;55:852–859.
- Maciel WG, da Silva KE, Croda J, Cayô R, Ramos AC, de Sales RO, et al. Clonal spread of carbapenem-resistant Acinetobacter baumannii in a neonatal intensive care unit. J Hosp Infect. 2018;98:300–304.
- Indhar F, Durrani MA, Bux A, Sohail M. Carbapenemases among Acinetobacter species isolated from NICU of a tertairy care hospital in Karachi. J Pak Med Assoc. 2017;67:1547–1551.
- Ulu-Kilic A, Gundogdu A, Cevahir F, Kilic H, Gunes T, Alp E. An outbreak of bloodstream infection due to extensively resistant Acinetobacter baumannii among neonates. Am J Infect Control. 2018;46:154–158.
- Karaaslan A, Soysal A, Altinkanat Gelmez G, Kepenekli Kadayifci E, Söyletir G, Bakir M. Molecular characterization and risk factors for carbapenem-resistant Gram-negative bacilli colonization in children: emergence of NDM-producing Acinetobacter baumannii in a newborn intensive care unit in Turkey. J Hosp Infect. 2016;92:67–72.
- Thomas R, Velaphi S, Ellis S, Walker AS, Standing JF, Heath P, et al. The use of polymyxins to treat carbapenem resistant infections in neonates and children. Expert Opin Pharmacother. 2019;20:415–422.
- Zusman O, Altunin S, Koppel F, Dishon Benattar Y, Gedik H, Paul M, et al. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother. 2017;72:29–39.
- Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother. 2014;58:654–663.
- Chen H, Liu Q, Chen Z, Li C. Efficacy of sulbactam for the treatment of Acinetobacter baumannii complex infection: A systematic review and meta-analysis. J Infect Chemother. 2017;23:278–285.
- Nowak J, Zander E, Stefanik D, Higgins PG, Roca I, Vila J, McConnell MJ. High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. J Antimicrob Chemother. 2017;72:3277–3282.
- Fragkou PC, Poulakou G, Blizou A, Blizou M, Rapti V, Karageorgopoulos DE, et al. The role of minocycline in the treatment of nosocomial infections caused by multidrug, extensively drug and pandrug resistant Acinetobacter baumannii: a systematic review of clinical evidence. Microorganisms. 2019;7:159.
- Leelasupasri S, Santimaleeworagun W, Jitwasinkul T. Antimicrobial susceptibility among colistin, sulbactam, and fosfomycin and a synergism study of colistin in combination with sulbactam or fosfomycin against clinical isolates of carbapenem-resistant Acinetobacter baumannii. J Pathog. 2018;2018:1–5.
- Nakwan N, Chokephaibulkit K, Imberti R. The use of colistin for the treatment of multidrug-resistant gram-negative infections in neonates and infants: a review of the literature. Pediatr Infect Dis J. 2019;38:1107–1112.
- Russo A, Bassetti M, Ceccarelli G, Carannante N, Losito AR, Bartoletti M, et al. Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: clinical features, therapy and outcome from a multicenter study. J Infect. 2019;79:130–138.
- Dickstein Y, AIDA Study Group, Lellouche J, Ben Dalak Amar M, Schwartz D, Nutman A, Daitch V, Yahav D, Amar M. Treatment Outcomes of colistin- and carbapenem-resistant Acinetobacter baumannii infections: an exploratory subgroup analysis of a randomized clinical trial. Clin Infect Dis. 2019;69:769–777.